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Acidic placental isoferritin inhibited the blastogenic response of peripheral human lymphocytes to T-cell activating lectins. We measured specific 
binding of radioiodinated placental isoferritin to cells of the T-cell line HD-MAR and found specific high-affinity binding. Binding was faster and 
more ferritin was bound at 37°C than at 4°C. Displacement experiments indicated that most of the binding occurred at the cell surface. Acidic 
placental ferritin and isolated H-type ferritin subunits but not isolated L-type subunits, competed for the binding. Scatchard plot analysis showed 
characteristics of a single binding species with a dissociation constant (&) of 1.34.4 x lo-” M. The results suggest the presence of receptors 
for acidic isoferritin on T-lymphocytes and thus, a regulatory role for the acidic ferritin H-type subunit in T-cell function. 
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1. INTRODUCTION 
Ferritin is an intracellular iron storage protein with 
an average molecular mass of 480 kDa. It is composed 
of at least two different types of subunits; an acidic, 
heavy (H) subunit and a more basic, light (L) subunit. 
These subunits assemble into a shell of 24 subunits [l] 
and their ratio in the ferritin molecule determines the 
surface charge of the molecule. Thus, ferritin rich in H- 
type will be more acidic than ferritin rich in L-type 
subunits [2]. Small amounts of ferritin are found in the 
serum of normal individuals while increased concentra- 
tions have been noted in the serum of patients with 
various proliferative disorders associated with impaired 
cell mediated immunity [3,4]. We have previously 
reported that ferritin inhibits the blastogenic response 
of peripheral human lymphocytes to T-cell activating 
lectins [3]. Using isoferritins isolated from human term 
placenta revealed that only the acidic isoferritin caused 
a marked suppression of phytohemagglutinin-induced 
blastogenesis [5]. We also found that peripheral lym- 
phocytes were able to bind iodinated ferritin [3]. These 
findings as well as the presence of ferritin on the sur- 
face of peripheral T-lymphocytes from patients with 
various malignant diseases [6-B] led us to the assump- 
tion that specific binding sites exist for acidic isoferritin 
on T-lymphocytes. In this paper we describe the 
specific, high-affinity binding of placental acidic isofer- 
ritin to the T-cell line HD-MAR. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The HD-MAR T-cell line is a continuous T-cell line established 
from a patient with Hodgkin’s lymphoma. Its T-cell characteristics 
have been previously defined [9]. Cells were cultured at 37°C in 5% 
COZ in air at a relative humidity above 90% in RPM1 1640 (Bio-Lab, 
Jerusalem, Israel) supplemented with 25% FCS (Gibco Labs, Grand 
Island, NY, USA), 100 U penicillin and 1OOpg streptomycin 
(Biological Industries, Beth Haemek, Israel) per ml. The cells were 
harvested in the log phase of growth, generally at day five and wash- 
ed free of FCS with 3 changes of RPM1 1640 containing 1% BSA and 
25 mM Hepes, pH 7.4. Cell number was determined with a 
hemocytometer. 
2.2. Ferritin 
Ferritin was isolated from human term placenta and fractionated 
into isoferritins as previously described [IO]. The acid ferritin used 
for the binding experiments was the ‘Acidic I’ fraction and the basic 
ferritin the ‘Basic I’ fraction. 
2.3. Ferritin subunit preparation 
This was carried out by simultaneous reduction and subunit 
dissociation of human intermediate placenta1 isoferritin with acetic 
acid and thioglycolic acid and gel chromatographic exchange into 
0.1% trifluoroacetic acid. The H- and L-ferritin subunits were 
separated by reverse-phase high performance liquid chromatography 
(HPLC) on a Spectra Physics liquid chromatograph using a Cl8 
reversed-phase column with a pore size of 300-A (Synchropak RP-P, 
25 cm x 4.1 mm i.d., SynChrom, USA) as described by Collawn et 
al. [ll]. 
2.4. Radioiodination procedure 
Correspondence address: A.M. Konijn, Department of Nutrition, 
The Hebrew University-Hadassah Medical School, PO BOX 1172, 
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‘Acidic I’ placental isoferritin was radioiodinated by solid-phase 
enzymatic radioiodination with Enzymobead (Bio-Rad Laboratories, 
Richmond, CA, USA) by the procedure advised by the manufacturer. 
This reagent consists of immobilized preparations of lactoperoxidase 
and glucose oxidase. Following iodination, and again before an ex- 
periment was done, “‘1-ferritin was separated from free iodine on a 
5 ml Biogel P-6 DC column (Bio-Rad). Using this method, the tl/z of 
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the iodinated ‘Acidic 1’ isoferritin was 142 days as determined by 
fluorogenic ELISA [12]. Before each experiment ‘251-acidic isofer- 
ritin concentration was measured by fluorogenic ELISA [13]. Free 
iodine was estimated by TCA precipitation and was generally less 
than 5%. 
2.5. Binding studies 
These were done in RPM1 1640 containing 25 mM Hepes, pH 7.4 
and 10 mg/ml BSA. Following three washes with the above medium, 
cells (1.5 x 106/ml) were incubated with 0.1-8.0 x lo-” M ?- 
‘Acidic 1’ isoferritin for 90 min (unless otherwise designated), in 
sterile polypropylene tubes. Binding was measured at 37°C and/or 
4°C. The cells were washed with ice-cold incubation medium not con- 
taining ferritin, transferred to new polystyrene tubes and the ‘251- 
acidic isoferritin bound was counted in a gamma-counter. Specific 
binding was measured by deducting the binding of 12%acidic isofer- 
ritin to the cells in the presence of a 500-fold unlabeled acidic isofer- 
ritin concentration. 
2.6. Competition studies 
Cells (106) were incubated in triplicates for 90 min at 37°C or 4°C 
in 0.5 ml incubation medium containing 4 x 10-r’ M “‘I-acidic 
isoferritin and increasing noniodinated concentrations of either 
‘Acidic I’ or ‘Basic I’ placental isoferritin, or HPLC-isolated H-type 
or L-type placental ferritin subunits. The cells were then washed and 
counted as described above. 
2.7. Displacement experiments 
Cells (106) were incubated with 16 x lo-” M “‘l-acidic isoferritin 
at 37°C for 90 min, thereafter unlabeled acidic isoferritin was added 
and the cells were incubated for additional 70 min. Cells were then 
washed and counted as described above. 
3. RESULTS 
1251-Placental acidic isoferritin bound specifically to 
the HD-MAR T-cell line at 37°C as well as at 4°C. 
Nonspecific binding was high and amounted in some 
experiments to 50% or more of the total binding (see 
Fig. 2). Nevertheless the specific binding was con- 
sistently and significantly elevated above the 
nonspecific binding. High levels of nonspecific binding 
of ferritin (up to 60% of the total binding) were also 
observed to erythroleukemia K562 cells [14] and rat 
hepatocytes [ 151. In further experiments the concentra- 
tion of albumin added to the medium in binding ex- 
periments was increased from 0.2 to l%, resulting in 
decreased nonspecific binding without affecting the 
specific binding. Consequently, specific binding was 
more than 50% of the total binding (see Fig. 5). 
Steady-state binding was reached after 60 min at 37°C 
and after 90 min at 4°C (Fig. 1). Binding at 4°C is con- 
sidered to be binding to the cell membrane, and binding 
at 37°C is thought to reflect both binding and inter- 
nalization of ferritin [ 161. In the described experiments, 
however, there was probably very little internalization 
at 37°C. As can be seen in Fig. 2, when cells were in- 
cubated with 1251-acidic isoferritin for 90 min and then 
for 70 min with a 500-fold excess of unlabeled ferritin, 
more than 80% of the specifically bound 1251-placental 
acidic isoferritin was replaced. Competition ex- 
periments with ‘Acidic I’ and ‘Basic I’ placental isofer- 
ritins, as well as with the HPLC-isolated acidic H-type 
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Fig. 1. Specific binding of ‘aXI-placental ‘Acidic I’ isoferritin to HD- 
MAR cells. Cells (2 x 106/ml) were incubated for the designated time 
period at 37°C or 4°C with 1.8 x 10-r’ M radioiodinated isoferritin. 
and basic L-type ferritin subunits, at 37°C and at 4°C 
indicated that the ferritin binding sites on the HD- 
MAR cell line were more specific for acidic than for 
basic isoferritins (Fig. 3). The isolated L-type subunit 
did not compete significantly with the radioiodinated 
acidic isoferritin for binding sites on the cell mem- 
brane. One could argue that the ferritin subunits 
isolated by HPLC were denatured, thereby resulting in 
nonspecific binding to the cells and masking of the 
competition experiments. This explanation is rather 
unlikely because the isolated subunits reassembled into 
intact apoferritin shells as assessed by gel elec- 
trophoretic analysis in 5% (T) polyacrylamide gels 
under non-reducing conditions (Fig. 4). In addition on- 
ly the H-type subunit competed for acidic ferritin bin- 
ding to HD-MAR cells while the L-type did not, 
accordingly the competition of the acidic H-type 
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Fig. 2. Displacement of ‘251-placental ‘Acidic I’ isoferritin. Cells 
(1.5 X 106/ml) were incubated for 90 min with 2 x 10-r’ M 
radioiodinated ferritin followed by lo-’ M nonradioactive ‘Acidic I’. 
Specific binding (O), nonspecific binding (a), total binding (A). 
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Fig. 3. Competition of placental isoferritins and ferritin subunits for 
ferritin binding sites on HD-MAR cells. Cells (106) were incubated in 
0.5 ml medium with 4 x 10-r’ M radioiodinated ‘Acidic I’ isoferritin 
and designated concentrations of unlabeled ferritin fractions, at 37°C 
or 4°C. A, ‘Acidic I’ placental isoferritin; B, ‘Basic I’ placental 
isoferritin; H, apoferritin of HPLC-isolated H-type ferritin subunits; 
L, apoferritin of HPLC-isolated L-type ferritin subunits. 
subunit for the binding of 1251-acidic isoferritin does 
not seem to be an artifact caused by denaturation of the 
subunits. Regardless, some denaturation of the HPLC- 
isolated H-type subunit was conceivable because the 
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Fig. 5. Specific placental ‘Acidic I’ isoferritin binding to HD-MAR 
cells as a factor of isoferritin concentration. Cells (106) were 
incubated in 0.6 ml medium at 37°C for 90 min. Specific binding 
(0), nonspecific binding (0). Insert, Scatchard plot. 
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Fig. 4. Analysis of ‘Acidic I’ placental isoferritin (A) and HPLC- 
isolated H-type subunits of ferritin (H), by electrophoresis on 5% (T) 
polyacrylamide gels under nonreducing conditions, showing 
reassembly of the subunits. 
isolated subunit did not compete as effectively as the 
‘Acidic I’ fraction for binding with tracer ‘Acidic I’ 
isoferritin. It has to be mentioned that the ‘Basic I’ 
placental isoferritin contained some H-type subunits 
[IO] and was therefore partially able to compete with 
H-type subunit binding sites on the cell. As shown in 
Fig. 5, increasing amounts of tracer acidic isoferritin 
added to the cells at 37°C led to saturable binding. The 
number of binding sites per cell in various experiments 
was calculated to be 98-460 per cell. By Scatchard plot 
analysis only a single binding species was found with a 
dissociation constant (&) of 1.3-4.4 X lo-” M 
(association constant (K) = 2.3-7.7 x 10” M). 
4. DISCUSSION 
Previous studies described by our group have shown 
a specific inhibitory effect of placental ‘Acidic I’ isofer- 
ritin on phytohemagglutinin-induced blastogenesis [5] 
and binding of ferritin to peripheral lymphocytes [3]. 
Placental ferritin has shown to be immunosuppressive 
in Hodgkin’s disease and in HIV infection [7,17]. A 
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high number of T-lymphocytes in cancer patients were 
found to have surface-bound ferritin [8] which was 
identified by a specific monoclonal antibody and it 
seemed to resemble placental isoferritin [18]. The fer- 
ritin associated with those lymphocytes could be 
removed only with the immunopotentiating reagent 
levamisol [6]. These results led us to assume that there 
are specific binding sites for acidic placental ferritin on 
T-lymphocytes. To prove this assumption we have used 
a continuous T-cell line, HD-MAR (established from a 
patient with Hodgkin’s lymphoma [9]) as a model 
system. It seems that placental ‘Acidic I’ isoferritin is 
attached to the surface of the cell at binding sites 
specific for the acidic isoferritin, most probably for the 
H-type subunit. The L-type subunit was not able to 
compete for these binding sites. The basic isoferritin 
does contain some H-type subunits [lo] and therefore 
was able to compete to some extent. The Scatchard plot 
analysis indicated that only one receptor species exists 
with a very high affinity for placental ‘Acidic I’ isofer- 
ritin. The low receptor number (98-460 per cell) and 
the high affinity (& = 1.3-4.4 x lo-” M) resemble 
receptors for other regulatory peptides such as the 
human interleukin-6 receptor [19]. Thus, it is possible 
that the H-type subunit of ferritin has a general 
regulatory effect on cell growth and proliferation. Ac- 
cordingly, H-type ferritin has an inhibitory effect on 
the proliferation of precursors of granulocytes and 
monocytes in cultured cells [20]. Consequently, the 
acidic heart ferritin but not the basic liver ferritin binds 
specifically to the promyelocytic cell line HL60 [21]. 
The inhibition of BFU-E colony formation by H-type 
ferritin and the specific binding of H-type ferritin to the 
human erythroleukemia cell line K562 have also been 
described [ 14,221. 
The effect of temperature on ferritin binding seems 
to be controversial. While some authors reported bin- 
ding of ferritin to HL60 [21], K562 [14] and guinea pig 
reticulocytes [23] only at 37”C, others found ferritin 
binding to K562 [22], HeLa cells [24] and rat 
hepatocytes [16] at 37°C as well as at 4°C. Our results 
indicate significant acidic isoferritin binding to HD- 
MAR cells at 37°C and to a lesser extent at 4°C. The 
evidence presented here suggests the occurrence on T- 
cells of specific, high-affinity receptors for H-subunit- 
rich placental isoferritin. It further points towards a 
regulatory role [5,17,25] of the ferritin H-type subunit 
in cellular immunity. 
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